Circassia is a specialty biopharmaceutical company focused on respiratory disease and allergy. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians, and we have a broad pipeline of asthma, COPD and allergy treatments in development.
Our asthma management products
Our novel, market-leading NIOX® products are used by specialists around the world to aid asthma diagnosis and management. We sell NIOX® direct in the United States and Germany, and we are currently expanding our geographical presence in Europe and strengthening our team in China. Our NIOX® products are also supplied in many other countries through our international network of partners.
Our allergy pipeline
Our development pipeline includes a range of treatments for allergy. Our immunotherapy targeting cat allergy has recently completed a phase III study with unexpected, disappointing results. It is the first in the new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs) and three of our other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. We are currently awaiting results from a large field study in Spring 2017 to inform our approach in allergy.
Our respiratory pipeline
Our lead asthma product, Fliveo®, targets substitution of GSK’s Flixotide® pMDI, and was recently approved in the UK and Sweden under the European decentralized procedure. We expect a further filing for regulatory approval by the end of 2017 for Seriveo®, our product targeting direct substitution of Seretide® pMDI. We are also developing a number of novel specialty treatments for chronic obstructive pulmonary disease.
Circassia was established in 2006, and in March 2014 we completed an initial public offering on the London Stock Exchange. In June 2015, we completed the acquisitions of Aerocrine and Prosonix as part of our strategy to independently commercialize our products and broaden our pipeline.